EOS 984
Alternative Names: EOS-301984; EOS-984Latest Information Update: 09 Apr 2024
At a glance
- Originator iTeos Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Equilibrative nucleoside transporter 1 modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 07 Apr 2024 Pharmacodynamics data from preclinical studies in Cancer released by iTeos Therapeutics
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 01 Jan 2024 iTeo Therapeutics has patent protection for EOS 984 in the US, Australia, Europe and China